Market Place
Sourcing Support
Venatorx Pharmaceuticals Announces Changes to Executive Leadership
16 May 2024 //
BUSINESSWIRE
Venatorx Pharmaceuticals Expands Senior Leadership Team
12 Mar 2024 //
BUSINESSWIRE
Venatorx and Melinta Provide Update on Status of NDA for Cefepime-Taniborbactam
23 Feb 2024 //
BUSINESSWIRE
New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3
20 Feb 2024 //
BUSINESSWIRE
Venatorx and Menarini Enter Agreement for Cefepime-Taniborbactam
09 Jan 2024 //
BUSINESSWIRE
Venatorx Announces Presentation of Analysis of Cefepime-Taniborbactam
16 Oct 2023 //
BUSINESSWIRE
Venatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract
10 Oct 2023 //
BUSINESSWIRE
Venatorx Pharmaceuticals to Present at IDWeek 2023
27 Sep 2023 //
BUSINESSWIRE
Venatorx Receives FDA Acceptance of NDA for Cefepime-Taniborbactam
15 Aug 2023 //
PR NEWSWIRE
Venatorx Announces FDA Acceptance of NDA for Cefepime-Taniborbactam
15 Aug 2023 //
BUSINESSWIRE
Venatorx Pharmaceuticals Appoints Tomas J. Heyman as Non-Executive Chairman
07 Mar 2023 //
BUSINESSWIRE
Venatorx Pharmaceuticals Announces Organizational Changes
20 Dec 2022 //
BUSINESSWIRE
Venatorx Presents Data on Investigational Cefepime-Taniborbactam at IDWeek 2022
20 Oct 2022 //
BUSINESSWIRE
Venatorx Pharmaceuticals to Present at IDWeek 2022
11 Oct 2022 //
BUSINESSWIRE
Venatorx Pharmaceuticals Raises Series C Financing Led by the AMR Action Fund
04 Apr 2022 //
BUSINESSWIRE
Venatorx Reports Positive Results from Phase 3 Cefepime-Taniborbactam Trial
10 Mar 2022 //
PRNEWSWIRE
Venatorx Pharmaceuticals Names Scott McConnell as VP, Medical Affairs
02 Dec 2021 //
BUSINESSWIRE
Venatorx Names Scott McConnell, as Vice President, Medical Affairs
02 Dec 2021 //
BUSINESSWIRE
Venatorx, Roche Collaborate to Develop New Class of Antibiotics
01 Nov 2021 //
BUSINESSWIRE
Venatorx Pharmaceuticals Provides Update on Cefepime-Taniborbactam
17 Aug 2021 //
BUSINESSWIRE
Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145
29 Jul 2021 //
BUSINESSWIRE
Venatorx Names Mary Beth Dorr, Ph.D. Vice President, Clinical Science
29 Jun 2021 //
BUSINESSWIRE
Venatorx Announces First Patient Dosed in Phase 1 Study of VNRX-9945
28 Jun 2021 //
BUSINESSWIRE
Venatorx Pharmaceuticals Expands Anti-Infective Portfolio with HBV Candidate
10 Mar 2021 //
BUSINESSWIRE
Venatorx Names Robert Waltermire, Ph.D. Senior VP, CMC
24 Nov 2020 //
BUSINESSWIRE
Venatorx Pharma to Present Data on Cefepime-Taniborbactam at IDWeek 2020
21 Oct 2020 //
BUSINESSWIRE
Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors
27 Jul 2020 //
BUSINESSWIRE
Venatorx & GARDP Partner to Develop New Antibiotic for Hospital Infections
29 Apr 2020 //
YAHOO
Venatorx and GARDP Partner to Develop New Antibiotic
28 Apr 2020 //
BUSINESSWIRE
Venatorx Pharma & GARDP Partner to Develop New Antibiotic for Hospital
28 Apr 2020 //
BUSINESSWIRE
